Industrial Genetic Toxicology Discussion Group Autumn Meeting 1990: In Vitro Activation Systems

Mutagenesis ◽  
1991 ◽  
Vol 6 (3) ◽  
pp. 237-238
Author(s):  
B. M. Elliott
1996 ◽  
Vol 24 (4) ◽  
pp. 603-608
Author(s):  
Moreno Paolini ◽  
Laura Pozzetti ◽  
Renata Mesirca ◽  
Andrea Sapone ◽  
Paola Silingardi ◽  
...  

The use of sodium phenobarbital (PB, CYP2B1 inducer) combined with β-naphthoflavone (β-NF, 1A1) to induce certain Phase I reactions in S9 liver fractions is a standard method for conducting short-term bioassays for genotoxicity. However, because post-oxidative enzymes are also able to activate many precarcinogens, we tested the possibility of adapting S9 liver fractions derived from Phase II-induced rodents to the field of genetic toxicology. In this study, S9 liver fractions derived from Swiss albino CD1 mice fed 7.5g/kg 2-(3)-tert-butyl-4-hydroxyanisole (BHA; a monofunctional Phase II-inducer) for 3 weeks, show a clear pattern of induction with an approximately 3.5–9.5-fold increase in glutathione S-transferase activity. In vitro DNA binding of the promutagenic agents, [14C]-l,4-dichlorobenzene (DCB) and [14C]-1,4-dibromobenzene (DBB), is mediated by such metabolic liver preparations and showed a significant increase in covalent binding capability. In some instances, enzyme activity was more elevated when compared to that obtained with traditional (Phase I-induced) S9. Together with DNA binding, the genetic response of these chemicals in the diploid D7 strain of Saccharomyces cerevisiae used as a biological test system, revealed the ability of the BHA-derived preparations to activate the promutagenic agents, as exemplified by the significant enhancement of mitotic gene-conversion (up to 5.2-fold for DCB and 3.4-fold for DBB) and reverse point mutation (up to 3.6-fold for DCB and 2.5-fold for DBB) at a 4mM concentration. This novel metabolising biosystem, with enhanced Phase II activity, is recommended together with a traditional S9, for detecting unknown promutagens in genotoxicity studies. The routine use of either oxidative or post-oxidative S9 increases the responsiveness of the test and can contribute to the identification of promutagens not detected when using traditional protocols.


1984 ◽  
Vol 259 (5) ◽  
pp. 3173-3180 ◽  
Author(s):  
P Grandics ◽  
A Miller ◽  
T J Schmidt ◽  
D Mittman ◽  
G Litwack

Author(s):  
Simon Villegas-Ospina ◽  
Wbeimar Aguilar-Jimenez ◽  
Sandra M. Gonzalez ◽  
María T. Rugeles

AbstractObjective:Vitamin D (VitD) is an anti-inflammatory hormone; however, some evidence shows that VitD may induce the expression of activation markers, such as CD38 and HLA-DR. We explored its effect on the expression of these markers on CD4Materials and methods:CD38 and HLA-DR expression was measured by flow cytometry in PHA/IL-2-activated mononuclear cells cultured under VitD precursors: three cholecalciferol (10Results:Cholecalciferol at 10Conclusion:Although no significant correlations were observed in vivo in healthy subjects, VitD treatment in vitro modulated immune activation by increasing the expression of CD38 and decreasing the proliferation of HLA-DR


Development ◽  
1974 ◽  
Vol 31 (3) ◽  
pp. 635-642
Author(s):  
M. H. Kaufman ◽  
R. L. Gardner

Parthenogenetic mouse embryos were selected following in vitro activation, and transferred to the oviducts of pseudopregnant recipients. Decidua was evoked by 50–56% of diploid parthenogenones compared to 35·1% of haploid embryos with a single pronucleus, 37·5% of immediate cleavage eggs and 77% of fertilized eggs (controls). On day 4, 58·7% of diploid parthenogenones were morphologically normal morulae or blastocysts; over 90% of these ‘normal’ embryos evoked decidua when retransferred to recipients compared to 8·9% of abnormal embryos flushed from the ‘transfer’ sides, suggesting that only ‘normal’ embryos could evoke decidua. Potentially diploid parthenogenones remained diploid on chromosomal examination on day 4.


Sign in / Sign up

Export Citation Format

Share Document